{"id":"W7116899690","doi":"10.1002/ijgo.70676","title":"Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecology & Obstetrics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Eisai Canada; Eisai; AstraZeneca","keywords":"Clinical trial; Phases of clinical research; Phase (matter); Ovary; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001801767,0.0007144551,0.0009956454,0.0001960488,0.000219105,0.000433016,0.0004324167,0.0005956179,0.001628682],"category_scores_gemma":[0.0008564448,0.0002641122,0.0005065529,0.0002107823,0.0004372187,0.0004397138,0.000274903,0.00146632,0.0003156701],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007179754,"about_ca_system_score_gemma":0.00068196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004296629,"about_ca_topic_score_gemma":0.0008246825,"domain_scores_codex":[0.9995535,0.0002585252,0.00002361659,0.00005696217,0.00004825869,0.00005914662],"domain_scores_gemma":[0.9993516,0.0001522916,0.0001411225,0.00008022375,0.00005281325,0.0002219836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5610223,0.0568122,0.03741552,0.0009556843,0.001571308,0.0008811372,0.0006673149,0.004143682,0.1425273,0.0002851193,0.004726358,0.1889919],"study_design_scores_gemma":[0.3412457,0.5744424,0.06081066,0.00003637468,0.0005069114,0.001036999,0.00007551694,0.001775646,0.01493564,0.0001159689,0.004990523,0.00002773142],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976882,0.0007530287,0.0001672206,0.0001289662,0.00001288223,0.0004781477,0.0001962762,0.00002353162,0.0005518286],"genre_scores_gemma":[0.9971544,0.0003729362,0.0005103525,0.000206935,0.00002965882,0.0004222557,0.0007819975,0.000007226985,0.0005142092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001801767,"threshold_uncertainty_score":0.009528816,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02002530114979614,"score_gpt":0.3552855373166141,"score_spread":0.3352602361668179,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}